Vabicaserin (PF-05208769) / Pfizer  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vabicaserin (PF-05208769) / Pfizer
NCT00265551: Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

Completed
2
300
US
SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg), placebo
Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
 
01/07
NCT00563706: Study Evaluating Vabicaserin in Subjects With Schizophrenia

Completed
2
199
US, Canada
vabicaserin, risperidone, placebo
Pfizer
Schizophrenia
06/08
06/08
NCT00768612: Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia

Withdrawn
2
0
Japan
SCA-136 50mg/day, SCA-136 150 mg/day, SCA-136 300mg/day, Risperidone 4mg/day
Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
07/09
07/09

Download Options